Team:British Columbia

UBC iGEM 2021

problem overview

Our Solution

We want to create a bacterial platform that can report on tumour immune status in-vivo, and generate a reporter that can be easily retrieved in blood or urine.

solution pipeline

[1] Sharma, P. et al. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707–723.

[2] Bonaventura, P. et al. (2019). Cold tumors: A therapeutic challenge for immunotherapy. Frontiers in Immunology, 10.

[3] Pilard, C. et al. (2021). Cancer immunotherapy: It’s time to better predict patients’ response. British Journal of Cancer.

[4] Galli, F. et al. (2020). Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental & Clinical Cancer Research, 39(1).